Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A phase i/ii, open-label, single-arm, two-part trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma
Protocol ID
CO43810
Disease (Sub Disease)
Non-hodgkin lymphoma
Diagnosis Stage
Relapsed/refractory
Location
QLD, WA
Sponsor
Hoffmann-La Roche
Links
Trial Status
Open
Sites
Queensland Children's Hospital
Perth Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 Months to 30 Years
International registry ID's
NCT05533775
| Study Title | A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma |
|---|---|
| Protocol ID | CO43810 |
| Disease (Sub Disease) | Non-hodgkin lymphoma |
| Diagnosis Stage | Relapsed/refractory |
| Location | QLD / WA |
| Sponsor | Hoffmann-La Roche |
| Links | https://clinicaltrials.gov/ct2/show/NCT05533775 |
| Trial Status | Open |
| Trial Open Date | 16/11/2022 |
| Sites | Queensland Children's Hospital / Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 6 Months to 30 Years |
| International registry ID's | NCT05533775 |